Inhibrx Biosciences, Inc. disclosed a September investor presentation in an 8-K filing, detailing financial position and clinical trial data for its lead candidate INBRX-106. The company reported holding $219.5 million in cash and cash equivalents as of August 6, 2026. The presentation outlines a strategic focus on next-generation OX40 agonism to enhance the efficacy of PD-1 inhibitors in various cancer types.
The company highlighted data from the HexAgon study, which compares INBRX-106 in combination with pembrolizumab against pembrolizumab monotherapy in first-line head and neck squamous cell carcinoma (HNSCC). In the overall population, the combination therapy demonstrated an objective response rate (ORR) of 80% compared to 33% for monotherapy. The complete response rate was 30% for the combination versus 0% for monotherapy. Progression-free survival (PFS) was not reached for the combination group, whereas the median PFS for monotherapy was 4.6 months. The PFS6 rate, indicating the proportion of patients without progression at six months, was 90% for the combination compared to 33% for monotherapy.
In a specific subset of patients with HPV-positive HNSCC, the combination therapy showed an ORR of 48.3% versus 26.5% for pembrolizumab alone. The complete response rate in this subset was 13.8% compared to 0%. Median PFS was 9.6 months for the combination versus 4.9 months for monotherapy, with a PFS6 rate of 72.4% versus 42.8%. The company stated that these clinical results are supported by immunological data showing T-cell proliferation increased by up to 15-fold and activation increased by up to 4-fold compared to pembrolizumab alone.
Inhibrx described HPV-positive HNSCC as an open market exceeding $4 billion. The company noted that expanding the Phase 2 portion of the HexAgon study to include 50 additional HPV-positive patients may serve as a potential path to accelerated approval by the end of 2028 or early 2029. Broader commercial opportunities are cited in bladder cancer, non-small cell lung cancer, melanoma, MSI-high/TMB-high tumors, and triple-negative breast cancer, representing a potential market exceeding $50 billion.
The presentation outlined near-term milestones for ozekibart (INBRX-109), another product candidate. Inhibrx plans to meet with the U.S. Food and Drug Administration to discuss registrational trial design for first-line colorectal cancer and a potential accelerated regulatory pathway for fourth-line colorectal cancer. Interim data from combination cohorts in colorectal cancer is expected in the second half of 2026. The company also projects potential approval and first commercial launch of ozekibart for metastatic or unresectable chondrosarcoma in the second half of 2027.
For INBRX-106, the initiation of the Phase 3 portion of the HexAgon study is planned for the first half of 2027. Interim data from a perioperative non-small cell lung cancer study is also anticipated during this period. The company emphasized that its investigational product candidates have not been approved or licensed by the FDA or any other regulatory authority and are not commercially available. The presentation includes forward-looking statements regarding business strategy, clinical trial timing, and financial projections, which involve risks and uncertainties that could cause actual results to differ materially.